Search
bexagliflozin (Brenzavvy)
Indications:
- treatment of adults with diabetes mellitus type 2
Dosage:
- 20 mg PO QD
Dosage adjustment in renal failure:
- approved for use in adults with eGFR > 30 mL/min/1.73m2
Adverse effects:
- ketoacidosis
- lower limb amputation
- volume depletion
- urosepsis
- pyelonephritis
- Fournier's gangrene
- genital mycotic infections
- hypoglycemia
Drug interactions:
- hypoglycemia when used in combination with insulin or drugs that enhance insulin secretion (sulfonylurea)
Mechanism of action:
- reduction of blood glucose by increasing glucosuria
- all flozins inhibit sodium-glucose cotransporter 2 (SGLT2) thus inhibiting reuptake of glucose by the renal tubules
Interactions
drug adverse effects of hypoglycemic agents
General
SGLT-2 inhibitor; oral glucosuric agent; flozin
References
- Tucker ME
FDA Approves New Type 2 Diabetes Drug Bexagliflozin
Medscape. Jan 23. 2023
https://www.medscape.com/viewarticle/987345